SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD - UMCG, Groningen, The Netherlands

Video navigation menu

SGLT2i trials, including the DAPA-HF 01:10
Case presentation 04:03
(Diuretic) effects of SGLT2i? 07:20
SGLT2i and the kidney 08:46
Another tool in our box for management of HFrEF 11:08

Educational information

This video by prof. De Boer, MD, PhD is part of the 3rd Groningen Heart Failure symposium "How to implement the newest heart failiure therapies? - A case-based approach".

Faculty

Prof. Rudolf de Boer is a Clinical Cardiologist and a Professor of (translational) Cardiology at the University Medical Center Groningen, the Netherlands.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by unrestricted educational grants from AstraZeneca, Pfizer, Vifor and Novartis.

Click here for the introduction of this symposium Watch other presentations in this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.